Bioventus Statistics
Total Valuation
Bioventus has a market cap or net worth of $832.50 million. The enterprise value is $1.04 billion.
Important Dates
The last earnings date was Monday, November 2, 2026, after market close.
| Earnings Date | Nov 2, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Bioventus has 84.26 million shares outstanding. The number of shares has increased by 3.97% in one year.
| Current Share Class | 68.47M |
| Shares Outstanding | 84.26M |
| Shares Change (YoY) | +3.97% |
| Shares Change (QoQ) | +2.34% |
| Owned by Insiders (%) | 2.63% |
| Owned by Institutions (%) | 46.10% |
| Float | 34.06M |
Valuation Ratios
The trailing PE ratio is 12.21 and the forward PE ratio is 12.00. Bioventus's PEG ratio is 1.09.
| PE Ratio | 12.21 |
| Forward PE | 12.00 |
| PS Ratio | 1.42 |
| Forward PS | 1.34 |
| PB Ratio | 2.81 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 9.80 |
| P/OCF Ratio | 9.52 |
| PEG Ratio | 1.09 |
Financial Ratio History Enterprise Valuation
The stock's EV/EBITDA ratio is 13.47, with an EV/FCF ratio of 12.28.
| EV / Earnings | 18.21 |
| EV / Sales | 1.78 |
| EV / EBITDA | 13.47 |
| EV / EBIT | 17.67 |
| EV / FCF | 12.28 |
Financial Position
The company has a current ratio of 1.68, with a Debt / Equity ratio of 0.84.
| Current Ratio | 1.68 |
| Quick Ratio | 1.09 |
| Debt / Equity | 0.84 |
| Debt / EBITDA | 2.95 |
| Debt / FCF | 2.87 |
| Interest Coverage | 3.38 |
Financial Efficiency
Return on equity (ROE) is 25.78% and return on invested capital (ROIC) is 11.65%.
| Return on Equity (ROE) | 25.78% |
| Return on Assets (ROA) | 5.37% |
| Return on Invested Capital (ROIC) | 11.65% |
| Return on Capital Employed (ROCE) | 11.45% |
| Weighted Average Cost of Capital (WACC) | 7.22% |
| Revenue Per Employee | $610,041 |
| Profits Per Employee | $59,683 |
| Employee Count | 960 |
| Asset Turnover | 0.85 |
| Inventory Turnover | 2.04 |
Taxes
| Income Tax | -24.20M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +47.02% in the last 52 weeks. The beta is 0.62, so Bioventus's price volatility has been lower than the market average.
| Beta (5Y) | 0.62 |
| 52-Week Price Change | +47.02% |
| 50-Day Moving Average | 12.81 |
| 200-Day Moving Average | 11.12 |
| Relative Strength Index (RSI) | 28.91 |
| Average Volume (20 Days) | 712,495 |
Short Selling Information
The latest short interest is 3.02 million, so 3.59% of the outstanding shares have been sold short.
| Short Interest | 3.02M |
| Short Previous Month | 3.18M |
| Short % of Shares Out | 3.59% |
| Short % of Float | 8.88% |
| Short Ratio (days to cover) | 7.30 |
Income Statement
In the last 12 months, Bioventus had revenue of $585.64 million and earned $57.30 million in profits. Earnings per share was $0.81.
| Revenue | 585.64M |
| Gross Profit | 402.35M |
| Operating Income | 59.05M |
| Pretax Income | 40.13M |
| Net Income | 57.30M |
| EBITDA | 77.49M |
| EBIT | 59.05M |
| Earnings Per Share (EPS) | $0.81 |
Full Income Statement Balance Sheet
The company has $33.03 million in cash and $244.15 million in debt, with a net cash position of -$211.12 million or -$2.51 per share.
| Cash & Cash Equivalents | 33.03M |
| Total Debt | 244.15M |
| Net Cash | -211.12M |
| Net Cash Per Share | -$2.51 |
| Equity (Book Value) | 291.87M |
| Book Value Per Share | 3.51 |
| Working Capital | 107.84M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was $87.43 million and capital expenditures -$2.45 million, giving a free cash flow of $84.99 million.
| Operating Cash Flow | 87.43M |
| Capital Expenditures | -2.45M |
| Depreciation & Amortization | 18.45M |
| Net Borrowing | -93.25M |
| Free Cash Flow | 84.99M |
| FCF Per Share | $1.01 |
Full Cash Flow Statement Margins
Gross margin is 68.70%, with operating and profit margins of 10.08% and 9.78%.
| Gross Margin | 68.70% |
| Operating Margin | 10.08% |
| Pretax Margin | 6.85% |
| Profit Margin | 9.78% |
| EBITDA Margin | 13.23% |
| EBIT Margin | 10.08% |
| FCF Margin | 14.51% |
Dividends & Yields
Bioventus does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.97% |
| Shareholder Yield | -3.97% |
| Earnings Yield | 8.19% |
| FCF Yield | 10.21% |
Analyst Forecast
The average price target for Bioventus is $16.60, which is 68.02% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $16.60 |
| Price Target Difference | 68.02% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 5.77% |
| EPS Growth Forecast (3Y) | 14.00% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Bioventus has an Altman Z-Score of 1.75 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.75 |
| Piotroski F-Score | 7 |